https://www.selleckchem.com/products/stx-478.html
Most program directors (77%) perceive sleep disorders as a problem in CF and would recommend routine sleep screening. Possible barriers to sleep screening included clinic flow, screening fatigue, and lack of recommendations for sleep screening. Formal sleep screening is inconsistent among CF care centers although most survey respondents would recommend the inclusion of screening in routine CF care. Future work is needed to further evaluate the impact of sleep disorders in CF and determine best practices for standardization of sleep scre

https://www.selleckchem.com/products/apd334.html
Recent revolution in oncology treatment has witnessed emergence and fast development of the targeted therapy and immunotherapy. In contrast to traditional cytotoxic agents, these types of treatment tend to be more tolerable and thus efficacy is of more concern. As a result, seamless phase I/II trials have gained enormous popularity, which aim to identify the optimal biological dose (OBD) rather than the maximum tolerated dose (MTD). To enhance the accuracy and robustness for identification of OBD, we develop a calibration-free odds (CFO)